1. Home
  2. RDHL vs DRMA Comparison

RDHL vs DRMA Comparison

Compare RDHL & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Redhill Biopharma Ltd.

RDHL

Redhill Biopharma Ltd.

HOLD

Current Price

$0.97

Market Cap

5.4M

Sector

Health Care

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.25

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDHL
DRMA
Founded
2009
2014
Country
Israel
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4M
5.1M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
RDHL
DRMA
Price
$0.97
$1.25
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
56.4K
57.7K
Earning Date
04-27-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$381.91
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$0.59
52 Week High
$3.31
$7.33

Technical Indicators

Market Signals
Indicator
RDHL
DRMA
Relative Strength Index (RSI) 57.91 45.45
Support Level $0.91 $1.13
Resistance Level $1.07 $1.40
Average True Range (ATR) 0.07 0.08
MACD 0.00 0.00
Stochastic Oscillator 64.38 25.00

Price Performance

Historical Comparison
RDHL
DRMA

About RDHL Redhill Biopharma Ltd.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: